Loading…
Epigral (EPIGRAL)₹890.25−2.51%Specialty Chemicals
In the Jun 2026 quarter (consolidated), Epigral reported sales of ₹703 Cr, up 16.2% from Jun 2025, and net profit of ₹99.65 Cr, down 38.0% year on year. For the year to Mar 2026, sales were ₹2,517 Cr and net profit ₹331 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 477 | 471 | 524 | 649 | 623 | 643 | 625 | 605 | 585 | 595 | 733 | 703 |
| Expenses | 370 | 349 | 370 | 475 | 448 | 464 | 454 | 443 | 456 | 495 | 569 | 527 |
| Operating Profit | 108 | 123 | 156 | 176 | 179 | 184 | 174 | 164 | 132 | 103 | 168 | 180 |
| OPM % | 23.1% | 26.0% | 30.0% | 27.0% | 28.0% | 28.1% | 28.0% | 27.0% | 22.0% | 17.0% | 23.1% | 25.0% |
| Other Income | 0.99 | 1.99 | 2.01 | 1.99 | 5.99 | 4.01 | 3.99 | 9.01 | 1.99 | 6.01 | −0.99 | 4.99 |
| Interest | 20.95 | 19.95 | 13.97 | 13.97 | 26.94 | 0.00 | 11.98 | 22.95 | 21.95 | 10.99 | 15.99 | 6.99 |
| Depreciation | 32.01 | 31.01 | 30.02 | 32.98 | 31.99 | 33.02 | 33.99 | 42.02 | 41.98 | 42.99 | 42.01 | 43.03 |
| Profit before tax | 55.86 | 73.87 | 113 | 131 | 125 | 154 | 131 | 107 | 69.83 | 54.91 | 110 | 134 |
| Tax % | 32.0% | 34.0% | 32.0% | 34.0% | 35.0% | 33.0% | 34.0% | −50.0% | 26.0% | 28.0% | 26.0% | 25.0% |
| Net Profit | 37.91 | 48.85 | 76.75 | 85.74 | 80.73 | 104 | 86.70 | 161 | 50.82 | 38.90 | 80.75 | 99.65 |
| EPS (Rs) | 9.15 | 11.82 | 18.62 | 20.69 | 19.59 | 24.03 | 20.16 | 37.29 | 11.89 | 9.08 | 18.79 | 23.13 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 826 | 1,546 | 2,181 | 1,924 | 2,540 | 2,517 | 2,616 |
| Expenses | 568 | 1,041 | 1,501 | 1,451 | 1,840 | 1,962 | 2,046 |
| Operating Profit | 262 | 511 | 691 | 483 | 713 | 567 | 584 |
| OPM % | 32.0% | 33.0% | 31.0% | 25.0% | 28.0% | 22.1% | 22.3% |
| Other Income | 1.99 | 3.99 | 7.99 | 7.01 | 15.99 | 14.99 | 12.00 |
| Interest | 28.94 | 43.92 | 65.85 | 72.86 | 52.93 | 71.93 | 55.92 |
| Depreciation | 73.98 | 85.98 | 109 | 124 | 133 | 168 | 170 |
| Profit before tax | 161 | 382 | 521 | 290 | 540 | 340 | 368 |
| Tax % | 37.0% | 34.0% | 32.0% | 33.0% | 34.0% | 3.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 2.01 | — |
| Net Profit | 101 | 252 | 352 | 195 | 357 | 331 | 270 |
| EPS (Rs) | 24.50 | 60.92 | 85.11 | 47.20 | 82.98 | 77.05 | 62.89 |
| Dividend payout % | 0.0% | 0.0% | 6.0% | 11.0% | 7.0% | 6.0% | — |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 42.14 | 42.11 | 42.12 | 42.13 | 43.10 | 43.13 |
| Reserves | 433 | 685 | 1,030 | 1,215 | 1,863 | 2,183 |
| Borrowings | 755 | 994 | 881 | 966 | 594 | 573 |
| Other Liabilities | 223 | 407 | 486 | 579 | 658 | 715 |
| Total Liabilities | 1,453 | 2,128 | 2,438 | 2,801 | 3,158 | 3,515 |
| Fixed Assets | 1,106 | 1,072 | 1,811 | 1,774 | 2,246 | 2,127 |
| CWIP | 126 | 589 | 158 | 484 | 64.10 | 452 |
| Investments | 0.00 | 0.00 | 20.95 | 20.93 | 97.71 | 22.93 |
| Other Assets | 221 | 466 | 449 | 523 | 751 | 914 |
| Inventories | 54.21 | 154 | 213 | 264 | 389 | 350 |
| Trade receivables | 119 | 255 | 166 | 179 | 232 | 416 |
| Cash & equivalents | 0.99 | 24.93 | 14.96 | 6.98 | 21.93 | 4.98 |
| Total Assets | 1,453 | 2,128 | 2,438 | 2,801 | 3,158 | 3,515 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 229 | 284 | 625 | 397 | 441 | 435 |
| Cash from investing activity | −197 | −456 | −438 | −402 | −263 | −356 |
| Cash from financing activity | −31.93 | 195 | −199 | −7.98 | −164 | −93.79 |
| Net cash flow | 1.01 | 24.03 | −11.01 | −11.01 | 15.01 | −14.01 |
| Capex | 197 | 455 | 416 | 398 | 195 | 394 |
| Free cash flow | 31.95 | −172 | 210 | −0.99 | 254 | 49.96 |
| CFO / OP % | 99.0% | 68.0% | 106.1% | 93.0% | 78.1% | 90.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 51 | 59 | 27 | 33 | 32 | 59 |
| Inventory days | 50 | 73 | 68 | 89 | 104 | 88 |
| Days payable | 70 | 43 | 37 | 64 | 51 | 67 |
| Cash conversion cycle | 35 | 93 | 62 | 62 | 89 | 84 |
| Working capital days | −93 | −27 | −42 | −55 | 25 | 15 |
| ROCE % | — | 29.0% | 32.0% | 17.0% | 25.0% | 15.0% |
For the Jun 2026 quarter, Epigral reported sales of ₹703 Cr, up 16.2% year on year and net profit of ₹99.65 Cr, down 38.0% year on year. The operating margin was 25.0%.
Epigral's sales for the year to Mar 2026 were ₹2,517 Cr; over the last twelve months they were ₹2,616 Cr.
Net profit for the year to Mar 2026 was ₹331 Cr, and ₹270 Cr over the last twelve months. Earnings per share over the same trailing period were ₹62.89.
Epigral reported borrowings of ₹573 Cr at Mar 2026, against cash and equivalents of ₹4.98 Cr.
Cash from operations was ₹435 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹49.96 Cr.